

# Fumiharu Ohka

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5062160/publications.pdf>

Version: 2024-02-01

52  
papers

2,489  
citations

361413

20  
h-index

206112

48  
g-index

52  
all docs

52  
docs citations

52  
times ranked

5013  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mutational landscape and clonal architecture in grade II and III gliomas. <i>Nature Genetics</i> , 2015, 47, 458-468.	21.4	729
2	Targeting the Notch-regulated non-coding RNA TUG1 for glioma treatment. <i>Nature Communications</i> , 2016, 7, 13616.	12.8	267
3	Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. <i>Neuro-Oncology</i> , 2018, 20, 66-77.	1.2	225
4	Current Trends in Targeted Therapies for Glioblastoma Multiforme. <i>Neurology Research International</i> , 2012, 2012, 1-13.	1.3	142
5	The Global DNA Methylation Surrogate LINE-1 Methylation Is Correlated with MGMT Promoter Methylation and Is a Better Prognostic Factor for Glioma. <i>PLoS ONE</i> , 2011, 6, e23332.	2.5	95
6	Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation. <i>Tumor Biology</i> , 2014, 35, 5911-5920.	1.8	95
7	Chromatin Regulator PRC2 Is a Key Regulator of Epigenetic Plasticity in Glioblastoma. <i>Cancer Research</i> , 2013, 73, 4559-4570.	0.9	91
8	CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains. <i>Cancer Immunology Research</i> , 2016, 4, 259-268.	3.4	90
9	Epigenetic subclassification of meningiomas based on genome-wide DNA methylation analyses. <i>Carcinogenesis</i> , 2012, 33, 436-441.	2.8	76
10	Epigenetic dysregulation in glioma. <i>Cancer Science</i> , 2014, 105, 363-369.	3.9	58
11	Contribution of MicroRNA-1275 to Claudin11 Protein Suppression via a Polycomb-mediated Silencing Mechanism in Human Glioma Stem-like Cells. <i>Journal of Biological Chemistry</i> , 2012, 287, 27396-27406.	3.4	51
12	Aberrant TET1 Methylation Closely Associated with CpG Island Methylator Phenotype in Colorectal Cancer. <i>Cancer Prevention Research</i> , 2015, 8, 702-711.	1.5	47
13	Histone Deacetylase Inhibition in Prostate Cancer Triggers miR-320a Mediated Suppression of the Androgen Receptor. <i>Cancer Research</i> , 2016, 76, 4192-4204.	0.9	41
14	Neurocognitive and functional outcomes in patients with diffuse frontal lower-grade gliomas undergoing intraoperative awake brain mapping. <i>Journal of Neurosurgery</i> , 2020, 132, 1683-1691.	1.6	37
15	Significance of perivascular tumour cells defined by CD109 expression in progression of glioma. <i>Journal of Pathology</i> , 2017, 243, 468-480.	4.5	36
16	A hypoxia-inducible factor (HIF)-3 $\beta$ splicing variant, HIF-3 $\beta$ 4 impairs angiogenesis in hypervascular malignant meningiomas with epigenetically silenced HIF-3 $\beta$ 4. <i>Biochemical and Biophysical Research Communications</i> , 2013, 433, 139-144.	2.1	29
17	Supratotal Resection of Diffuse Frontal Lower Grade Gliomas with Awake Brain Mapping, Preserving Motor, Language, and Neurocognitive Functions. <i>World Neurosurgery</i> , 2018, 119, 30-39.	1.3	29
18	Urinary MicroRNA-Based Diagnostic Model for Central Nervous System Tumors Using Nanowire Scaffolds. <i>ACS Applied Materials &amp; Interfaces</i> , 2021, 13, 17316-17329.	8.0	27

#	ARTICLE	IF	CITATIONS
19	Organotypic brain explant culture as a drug evaluation system for malignant brain tumors. <i>Cancer Medicine</i> , 2017, 6, 2635-2645.	2.8	24
20	Assessment of Tumor Cells in a Mouse Model of Diffuse Infiltrative Glioma by Raman Spectroscopy. <i>BioMed Research International</i> , 2014, 2014, 1-8.	1.9	21
21	Peptide-based inhibition of the HOXA9/PBX interaction retards the growth of human meningioma. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 53-60.	2.3	20
22	Validation of a novel molecular RPA classification in glioblastoma (GBM-molRPA) treated with chemoradiation: A multi-institutional collaborative study. <i>Radiotherapy and Oncology</i> , 2018, 129, 347-351.	0.6	18
23	A novel all-in-one intraoperative genotyping system for IDH1-mutant glioma. <i>Brain Tumor Pathology</i> , 2017, 34, 91-97.	1.7	16
24	Immunohistochemical ATRX expression is not a surrogate for 1p19q codeletion. <i>Brain Tumor Pathology</i> , 2018, 35, 106-113.	1.7	16
25	Impact of the extent of resection on the survival of patients with grade II and III gliomas using awake brain mapping. <i>Journal of Neuro-Oncology</i> , 2021, 153, 361-372.	2.9	16
26	Activation of Yes-Associated Protein in Low-Grade Meningiomas Is Regulated by Merlin, Cell Density, and Extracellular Matrix Stiffness. <i>Journal of Neuropathology and Experimental Neurology</i> , 2015, 74, 704-709.	1.7	14
27	A novel high-sensitivity assay to detect a small fraction of mutant IDH1 using droplet digital PCR. <i>Brain Tumor Pathology</i> , 2018, 35, 97-105.	1.7	14
28	Neuroendoscopic Cylinder Surgery and 5-Aminolevulinic Acid Photodynamic Diagnosis of Deep-Seated Intracranial Lesions. <i>World Neurosurgery</i> , 2018, 116, e35-e41.	1.3	13
29	Applicable advances in the molecular pathology of glioblastoma. <i>Brain Tumor Pathology</i> , 2015, 32, 153-162.	1.7	12
30	An immuno-wall microdevice exhibits rapid and sensitive detection of IDH1-R132H mutation specific to grade II and III gliomas. <i>Science and Technology of Advanced Materials</i> , 2016, 17, 618-625.	6.1	12
31	Remote ischemic preconditioning protects human neural stem cells from oxidative stress. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2017, 22, 1353-1361.	4.9	10
32	Comparing the Efficacy of DeVIC Therapy and High-dose Methotrexate Monotherapy with Whole-brain Radiation Therapy for Newly-diagnosed Primary Central Nervous System Lymphoma: A Single Institution Study. <i>Anticancer Research</i> , 2017, 37, 5215-5223.	1.1	10
33	LATS2 Positively Regulates Polycomb Repressive Complex 2. <i>PLoS ONE</i> , 2016, 11, e0158562.	2.5	8
34	Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities. <i>Immunotherapy</i> , 2016, 8, 1393-1404.	2.0	8
35	Negative impact of leukoaraiosis on the incidence of brain metastases in patients with lung cancer. <i>Journal of Neuro-Oncology</i> , 2017, 135, 299-306.	2.9	8
36	Aberrant Active cis-Regulatory Elements Associated with Downregulation of RET Finger Protein Overcome Chemoresistance in Glioblastoma. <i>Cell Reports</i> , 2019, 26, 2274-2281.e5.	6.4	8

#	ARTICLE	IF	CITATIONS
37	Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas. <i>Cancer Research</i> , 2021, 81, 4861-4873.	0.9	7
38	Supratotal Resection of Gliomas With Awake Brain Mapping: Maximal Tumor Resection Preserving Motor, Language, and Neurocognitive Functions. <i>Frontiers in Neurology</i> , 2022, 13, .	2.4	7
39	Significance of low mTORC1 activity in defining the characteristics of brain tumor stem cells. <i>Neuro-Oncology</i> , 2017, 19, now237.	1.2	6
40	Rapid sensitive analysis of IDH1 mutation in lower-grade gliomas by automated genetic typing involving a quenching probe. <i>Cancer Investigation</i> , 2016, 34, 12-15.	1.3	6
41	Spontaneous Tumor Regression of Intracranial Solitary Fibrous Tumor Originating From the Medulla Oblongata: A Case Report and Literature Review. <i>World Neurosurgery</i> , 2019, 130, 400-404.	1.3	6
42	Pathogenic Epigenetic Consequences of Genetic Alterations in IDH-Wild-Type Diffuse Astrocytic Gliomas. <i>Cancer Research</i> , 2019, 79, 4814-4827.	0.9	6
43	Driver Genetic Mutations in Spinal Cord Gliomas Direct the Degree of Functional Impairment in Tumor-Associated Spinal Cord Injury. <i>Cells</i> , 2021, 10, 2525.	4.1	6
44	Reliability of IDH1-R132H and ATRX and/or p53 immunohistochemistry for molecular subclassification of Grade 2/3 gliomas. <i>Brain Tumor Pathology</i> , 2022, 39, 14-24.	1.7	6
45	Recent Molecular and Genetic Findings in Intramedullary Spinal Cord Tumors. <i>Neurospine</i> , 2022, 19, 262-271.	2.9	6
46	Characterization of Intraoperative Motor Evoked Potential Monitoring for Surgery of the Pediatric Population with Brain Tumors. <i>World Neurosurgery</i> , 2018, 119, e1052-e1059.	1.3	5
47	Next Generation Sequencing-Based Transcriptome Predicts Bevacizumab Efficacy in Combination with Temozolomide in Glioblastoma. <i>Molecules</i> , 2019, 24, 3046.	3.8	5
48	Genetic analysis in patients with newly diagnosed glioblastomas treated with interferon-beta plus temozolomide in comparison with temozolomide alone. <i>Journal of Neuro-Oncology</i> , 2020, 148, 17-27.	2.9	5
49	Intraoperative seizure outcome of levetiracetam combined with perampanel therapy in patients with glioma undergoing awake brain surgery. <i>Journal of Neurosurgery</i> , 2021, 135, 998-1007.	1.6	3
50	Treatment of Primary CNS Lymphoma with RMPV (Rituximab, Methotrexate, Procarbazine, Vincristine) Therapy : Challenges and Prospects. <i>Japanese Journal of Neurosurgery</i> , 2018, 27, 29-36.	0.0	2
51	Clinical Significance of Epigenetic Alterations in Glioblastoma. , 2015, , 339-350.		0
52	Intraoperative H3F3A K27M Mutation-based Diagnosis of Spinal Cord Intramedullary Tumor. <i>Spinal Surgery</i> , 2021, 35, 215-217.	0.0	0